Rivaroxaban Compared To Low Molecular Weight Heparin In Treatment Of Malignancy Associated Venous Thromboembolism

Robert D. McBane, Benjamin Simmons,Rayya A. Saadiq,Waldemar E. Wysokinski,Dalene Bott-Kitslaar,Charles J. Lenz,Paul R. Daniels,Kevin P. Cohoon,Aneel A. Ashrani,Charles L. Loprinzi

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2016）

引用 9|浏览8

暂无评分

摘要

Low molecular weight heparin (LMWH) is the guideline endorsed treatment of choice for cancer associated venous thromboembolism (VTE). Rivaroxaban offers a convenient potential alternative to LMWH; however there are no data comparing either the efficacy or safety of these two therapies in this

查看译文

关键词

malignancy associated venous thromboembolism,venous thromboembolism,low molecular weight heparin,rivaroxaban

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要